Blog
RSS FeedPosted by Michael Wonder on 17 Jan 2022
ATAGI update following weekly COVID-19 meeting (12 January 2022)
17 January 2022 - Previously, severely immunocompromised people aged 12 years and older were recommended to receive a third primary dose ...
Posted by Michael Wonder on 16 Jan 2022
COVID-19 vaccine weekly safety report (13 January 2022)
13 January 2022 - To 9 January 2022, the TGA has received 952 reports which have been assessed as likely to ...
Posted by Michael Wonder on 16 Jan 2022
COVID-19 vaccine weekly safety report (6 January 2022)
17 January 2022 - To 2 January 2022, the TGA has received 415 reports which have been assessed as likely to ...
Posted by Michael Wonder on 04 Jan 2022
TGA grants provisional determination to AstraZeneca for COVID-19 prophylaxis and treatment, tixagevimab and cilgavimab (Evusheld)
4 January 2022 - On 4 January 2022, the TGA granted a further provisional determination to AstraZeneca in relation to ...
Posted by Michael Wonder on 28 Dec 2021
COVID-19 vaccine weekly safety report (23 December 2021)
23 December 2021 - To 19 December 2021, the TGA has received 415 reports which have been assessed as likely to ...
Posted by Michael Wonder on 19 Dec 2021
ATAGI update following weekly COVID-19 meeting (15 December 2021)
18 December 2021 - On Wednesday 15 December 2021 ATAGI reviewed the latest developments relating to COVID-19 and COVID-19 vaccine safety. ...
Posted by Michael Wonder on 16 Dec 2021
COVID-19 vaccine weekly safety report (16 December 2021)
16 December 2021 - To 12 December 2021, the TGA has received approximately 290 reports of suspected adverse events identified as ...
Posted by Michael Wonder on 15 Dec 2021
TGA approves new medicine for paediatric cancer
15 December 2021 - Another new cancer medicine from AstraZeneca. ...
Posted by Michael Wonder on 14 Dec 2021
Access Consortium statement on COVID-19 medicines
14 December 2021 - Vaccines have played a critical role in fighting the COVID-19 pandemic. However, medicines can still play ...
Posted by Michael Wonder on 14 Dec 2021
mRNA manufacturing facility will deliver long term health benefits for Australians
14 December 2021 - Medicines Australia welcomes the announcement that Australia will manufacture mRNA vaccines in a deal struck with ...
Posted by Michael Wonder on 13 Dec 2021
Moderna vaccine deal to produce 100 million doses in Melbourne reached by Federal and Victorian Governments
13 December 2021 - Australia is poised to become the largest producer of mRNA vaccines outside the US and Europe ...
Posted by Michael Wonder on 13 Dec 2021
ACCC helps to protect Australians against medicine shortages caused by COVID-19
10 December 2021 - Medicine shortages from the COVID-19 pandemic will continue to be actively managed by Medicines Australia and ...
Posted by Michael Wonder on 12 Dec 2021
Australian Technical Advisory Group on Immunisation recommendations on the use of Spikevax (Moderna) as a COVID-19 booster vaccine
12 December 2021 - Spikevax (Moderna), also referred to as the Moderna COVID-19 vaccine, has been provisionally approved for use as ...
Posted by Michael Wonder on 12 Dec 2021
ATAGI statement on the Omicron variant and timing of COVID-19 booster vaccination
12 December 2021 - The COVID-19 vaccines used in Australia are critical in protecting against COVID-19 due to all variants, including ...
Posted by Michael Wonder on 09 Dec 2021
COVID-19 vaccine weekly safety report (9 December 2021)
9 December 2021 - To 5 December 2021, the TGA has received 389 reports which have been assessed as likely to ...